Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer

Peer Review reports

Original Submission
23 Mar 2011	Submitted	Original manuscript
29 Mar 2011	Author responded	Author comments - Martin Schlumberger
Resubmission - Version 2
29 Mar 2011	Submitted	Manuscript version 2
24 Jul 2011	Reviewed	Reviewer Report - Dirk Vordermark
9 Aug 2011	Author responded	Author comments - Martin Schlumberger
Resubmission - Version 3
9 Aug 2011	Submitted	Manuscript version 3
Publishing
11 Aug 2011	Editorially accepted
11 Aug 2011	Article published	10.1186/1471-2407-11-349

Back to article page